Are thyroid molecular tests (such as Afirma, ThyroSeq) validated for use on FNA thyroid nodule samples that are not Bethesda class 3-4?
Clinical scenario where an indeterminate pathology on initial FNA was followed by a “benign” result on a 2nd FNA.
Community PollStarted
In what clinical scenario is thyroid molecular testing warranted?
41 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Endocrinology · BMCWorking Well Occupational Health Clinic
Answered on
If the first biopsy was AUS and the second biopsy was Bethesda II, benign, the molecular test is not warranted. It is agreed that a second biopsy of a nodule that was AUS (Bethesda III) will be benign about 40% of the time. If the first biopsy was follciular neopasm/suspicioyus for FN (Bethesda IV),...
Join for free or sign in to see the full answer